

Discordance of retroperitoneal and thoracic histologic findings in patients with metastatic germ cell tumors at postchemotherapy residual tumor resection

Yue Che, Carolin Wöltjen, Achim Lusch, Christian Winter, Stephan Trainer, Moritz Schirren, Stefan Sponholz, Wolfram Trudo Knoefel, Peter Albers & Andreas Hiester

Article - Version of Record



Suggested Citation:

Che, Y., Wöltjen, C., Lusch, A., Winter, C., Trainer, S., Schirren, M., Sponholz, S., Knoefel, W. T., Albers, P., & Hiester, A. (2024). Discordance of retroperitoneal and thoracic histologic findings in patients with metastatic germ cell tumors at postchemotherapy residual tumor resection. *World Journal of Surgical Oncology*, 22, Article 185. <https://doi.org/10.1186/s12957-024-03467-6>

Wissen, wo das Wissen ist.

This version is available at:

URN: <https://nbn-resolving.org/urn:nbn:de:hbz:061-20250127-104329-9>

Terms of Use:

This work is licensed under the Creative Commons Attribution 4.0 International License.

For more information see: <https://creativecommons.org/licenses/by/4.0>

RESEARCH

Open Access



Discordance of retroperitoneal and thoracic histologic findings in patients with metastatic germ cell tumors at postchemotherapy residual tumor resection

Yue Che^{1*}, Carolin Wöltjen¹, Achim Lusch¹, Christian Winter¹, Stephan Trainer², Moritz Schirren², Stefan Sponholz², Wolfram Trudo Knoefel³, Peter Albers¹ and Andreas Hiester¹

Abstract

Introduction and objectives Postchemotherapy residual tumor resection (PC-RTR) is an important part of the multimodal treatment for patients with metastatic germ cell tumors. Simultaneous retroperitoneal and thoracic metastases often require consecutive surgical procedures. This study analyzes the histologic findings after abdominal and thoracic surgery in order to tailor the sequence and intensity of surgery.

Patients and methods From a total of 671 PC-RTRs from 2008 to 2021 we analyzed 50 patients with stage III non-seminomatous germ cell tumor (NSGCT) who had undergone both retroperitoneal and thoracic postchemotherapy residual tumor resection after first-line and salvage chemotherapy.

Results All patients included had stage III NSGCT. 39 and 11 patients received first-line and salvage chemotherapy, respectively. 45 (90%) patients received retroperitoneal resection first, followed by thoracic surgery. Three patients (6%) underwent thoracic surgery before retroperitoneal surgery and two patients (4%) underwent simultaneous surgery. Overall, the histology of retroperitoneal and thoracic specimens was discordant in 23% of cases. After first-line chemotherapy, of fourteen patients with necrosis in retroperitoneal histology, four patients had vital carcinoma in lung histology. In patients with teratoma in the retroperitoneum, the thoracic findings were concordant in most cases (78%). When teratomatous elements were also present in the orchiectomy specimen, concordance was 100%. After salvage chemotherapy, the discordance rate was 55%.

Conclusion The data presented in this study underline that retroperitoneal residual masses with necrosis cannot reliably predict histologic findings of thoracic specimens. Patients with teratoma in the retroperitoneum have a high likelihood of teratoma in the thoracic specimen.

*Correspondence:

Yue Che

Yue.Che@med.uni-duesseldorf.de

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Patient summary

In this report we compared the findings of metastatic testicular cancer patients who received thoracic and retroperitoneal surgery. We concluded that the findings of one location cannot entirely predict the results of another location.

Keywords Germ cell cancer, Retroperitoneal surgery, Thoracic surgery, Postchemotherapy

Introduction

Postchemotherapy residual tumor resection (PC-RTR) plays an important role in the treatment of metastatic germ cell tumors (GCTs), although 40% of residual tumors have only necrotic tissue, 10% and 50% of residual tumors harbor viable cancer or teratoma, respectively [1]. Because residual tumor masses often involve other organs (kidney, lung, liver) or major vessels, PC-RTR is challenging and sometimes requires adjunctive vascular or organ surgery. Currently, the available diagnostic tools are still not reliable enough to predict residual tumor histology [2–4]. The morbidity of retroperitoneal surgery alone ranges from 7 to 30% with a mortality rate of 1% [5, 6]. In cases of resection of multiple tumor sites morbidity rates increase to over 35% [7, 8] and surgery must be carefully weighed against oncologic risk of recurrence. In cases of multiple residual tumor sites, current EAU guidelines recommend starting surgery at the site with the highest residual volume.

In our review of the literature, we found few studies comparing the correlation between retroperitoneal and thoracic histology [8–13]. Steyerberg et al. reported a high correlation (89%) between of necrotic findings in retroperitoneal lymph node dissection (RPLND) and lung resection [11]. However, other studies have reported discordance of 23–30% between different anatomical sites, mainly between retroperitoneum and chest [8, 10, 14]. Kesler et al. reported a discordance rate between retroperitoneal and thoracic pathology of 30% or more depending on the pathology category [12]. Schirren et al. reported a 20% discordance between the histology of both lungs when bilateral resection was performed. The discordance between mediastinal and lung histology was even higher at 28% [9]. On the other hand, Besse et al. described a discordance of only 5% between histologic findings of both lungs [10].

The aim of this study is to review our own data to analyze whether histology of one anatomical site can be used as a predictive tool.

Patients and methods

Between 01/2008 and 03/2021, 671 patients underwent residual tumor resection for germ cell tumor (GCT) at our institution. We queried our database and identified 50 patients who underwent retroperitoneal and thoracic PC-RTR after first-line or salvage chemotherapy

for metastatic non-seminomatous germ cell tumor (NSGCT). In a retrospective design we analyzed abdominal and thoracic histologies.

Results

Patient characteristics are shown in Table 1. All patients had stage III NSGCT with retroperitoneal and thoracic metastases and underwent cisplatin-based chemotherapy followed by residual tumor resection. If not performed simultaneously, thoracic and retroperitoneal surgery was performed within 41 days (range 7–75 days) and no treatment was administered in between. Patients who received chemotherapy or radiotherapy between thoracic and abdominal resection were excluded from the study. Out of 50 patients, 10 had a good and intermediate prognosis, respectively. 30 patients had a poor prognosis according to IGCCCG.

39 patients underwent first line treatment with three patients undergoing primary high dose chemotherapy with cisplatin, ifosfamide and etoposide (VIP). 15 patients had bleomycin, etoposide and cisplatin (BEP) or etoposide and cisplatin (EP) and 21 patients had conventional dosed VIP.

Eleven patients underwent salvage chemotherapy, all of whom received the TI-CE regimen (paclitaxel [T] and ifosfamide [I] followed by high-dose carboplatin [C] and etoposide [E]). The order of resection site was based on tumor volume, beginning with the larger tumor. In 45 patients, retroperitoneal resection was performed before to thoracic surgery and in three cases, thoracic surgery was performed first. In two cases, thoracic and abdominal surgery were performed simultaneously. Median human chorionic gonadotropin (HCG) and alpha-fetoprotein (AFP) levels at the time of surgery were 0.3 mIU/ml (range: 0–27.9) and 3.5 µg/l (range 1.3–24.5) in the first-line group and 1.9 (range: 0–8.8) and 5.6 (range: 2.5–2818) in the salvage group. One patient had a manifestly elevated AFP marker of 2818 µg/l after salvage chemotherapy.

We compared retroperitoneal and thoracic histologic reports of PC-RTR after first-line chemotherapy and salvage chemotherapy. All patients received retroperitoneal PC-RTR via open midline laparotomy. Of the thoracic surgeries, 41 patients received pulmonary PC-RTR only (wedge resections of the lung), 6 patients received extrapulmonary (mediastinal, retrocrural and/or cervical

Table 1 Patient’s characteristics

Patients	n = 50
Age (years, median, range)	34 (16–51)
IGCCCG prognosis group	
good	10
intermediate	10
poor	30
Line of treatment	
First line	39
Salvage / further line	11
First line chemotherapy	
PEB / EP	15
VIP	21
Primary high dose (HD-VIP)	3
Salvage chemotherapy	
TI-CE	10
TIP	1
Timing of surgery	
retroperitoneal surgery first	45
thoracic surgery first	3
simultaneous surgery	2
Primary tumor	
testicular tumor	47
primary retroperitoneal / thoracic	3
Tumor markers before surgery, first line group	
HCG (mU/ml, median, range)	0.3 (0–27.9)
AFP (μg/l, median, range)	3.5 (1.3–24.5)
Tumor markers before surgery, salvage group	
HCG (mU/ml, median, range)	1.9 (0–8.8)
AFP (μg/l, median, range)	5.6 (2.5–2818)

lymphadenectomy) PC-RTR only, and 4 patients received combined pulmonary and extrapulmonary PC-RTR.

Tumor size, detailed resection sites and adjunctive surgery are described in Table 2.

Histological outcomes

Histopathologic results after chemotherapy often contain mixed components of vital carcinoma, teratoma, necrosis, fibrosis and tumor-free lymph nodes. For the sake of clarity, histopathologic results are simplified in this manuscript and only the “worst” pathology is reported in this order: vital carcinoma (including teratoma with somatic-type malignancy), teratoma, necrosis.

PC-RTR after first-line chemotherapy, table 3

39 patients underwent PC-RTR after first-line treatment. On retroperitoneal histology 23 patients had teratoma, two had vital carcinoma and 14 had necrosis. On thoracic histology 18 patients had teratoma, 6 had vital carcinoma and 15 had necrosis.

When comparing retroperitoneal and thoracic histologic findings, the results were discordant in 23% of the cases. The highest discordance rate (29%) was found in patients with necrosis on retroperitoneal histology. Among fourteen patients with necrosis on retroperitoneal histology, four patients had vital carcinoma on pulmonary histology, one had teratoma with somatic-type malignancy (sarcomatoid differentiation), one had embryonal carcinoma, and two had unspecified non-seminoma. The pulmonary histology specimens containing viable embryonal carcinoma or non-seminoma were mostly composed of necrosis and had a proportion of

Table 2 Tumor size, resection sites and adjunctive surgery

	Retroperitoneal surgery n = 50	
Prechemotherapy tumor size (mean)	86 mm (range 7–350 mm)	
Postchemotherapy tumour size (mean)	72 mm (range 6–400 mm)	
Adjunctive surgery	15 (30%)	nephrectomy 5 patients (10%) aortic replacement 2 patients (4%) resection IVC 2 patients (4%) vertebral replacement 2 patients (4%) liver biopsy/resection 5 patients (10%) bowel resection 4 patients (8%)
	Thoracic surgery n = 50	
Prechemotherapy tumor size (mean)	33 mm (range 9–110 mm)	
Postchemotherapy tumour size (mean)	27 mm (range 7–80 mm)	
Resection site		
pulmonary	45 (88%)	
left lung	33 (65%)	
right lung	35 (69%)	
both sides	24 (47%)	
Extrapulmonary	10 (20%)	
+ left lung	2 (4%)	
+ right lung	1 (2%)	
+ both sides	1 (2%)	
Exclusive (only extrapulmonary resection)	6 (12%)	

Table 3 Comparison of retroperitoneal and thoracic histologies after first-line chemotherapy (inclusion of pulmonary and extrapulmonary histologies). Discordances between retroperitoneal and thoracic findings were 23%

First-line n = 39		Thoracic (pulmonary and extrapulmonary)				discordance %
		necrosis	teratoma	vital tumor other than teratoma	total	
Retroperitoneal	necrosis	10	0	4	14	29%
	teratoma	5	18	0	23	22%
	vital tumor other than teratoma	0	0	2	2	0
	total	15	18	6	39	23%

Table 4 Comparison of retroperitoneal and thoracic histologies after salvage chemotherapy. In 55% of patients retroperitoneal and thoracic histology did not match

Salvage treatment n = 11		Thoracic (pulmonary and extrapulmonary)				discordance %
		necrosis	teratoma	vital tumor other than teratoma	total	
Retroperitoneal	necrosis	4	0	2	6	33%
	teratoma	2	1	0	3	67%
	vital tumor other than teratoma	1	1	0	2	100%
	total	7	2	2	11	55%

Table 5 Comparison of histologies of left and right sided pulmonary resection. Overall, 24 patients received bilateral pulmonal resection after either first-line or salvage therapy. Overall, 13% of histologies between left and right sided resection differed

Histology		Right lung			total	discordance %
		necrosis	teratoma	vital tumor other than teratoma		
Left lung	necrosis	12	2	0	14	17%
	teratoma	0	8	0	8	0%
	vital tumor other than teratoma	1	0	1	2	50%
	total	13	10	1	24	13%

viable tumor cells of 1–5%. In patients with retroperitoneal teratoma, the thoracic findings were concordant in most cases (78%). In patients with teratomous components in the orchiectomy specimen and the retroperitoneum, all had teratomous findings in the thoracic histology. Two patients had vital carcinoma in the retroperitoneum, specifically teratoma with somatic-type malignancy, and had similar thoracic findings.

When comparing retroperitoneal and only extrapulmonary thoracic histologies, the findings were concordant in 100% of the patients, eight of these patients had teratoma and one had teratoma with somatic-type malignancy (liposarcoma).

PC-RTR after salvage chemotherapy, table 4

Of the 11 patients who underwent PC-RTR after salvage chemotherapy, six patients had discordant histologic findings. On retroperitoneal histology three patients had teratoma, two had vital carcinoma (yolk sac tumor and choriocarcinoma), and six had necrosis. In thoracic histology, two patients had teratoma, two had vital carcinoma (embryonal carcinoma and unspecified non-seminoma), and seven had necrosis. Teratoma with somatic-type malignancy was not observed in this group. Of note, all patients with vital carcinoma in the retroperitoneum did not have vital carcinoma in the thoracic histology and vice versa. Only the patient with yolk sac

tumor in the retroperitoneum had a highly elevated AFP preoperatively. All the other patients had negative or slightly elevated tumor markers.

Comparison of left and right sided pulmonary resection, table 5

Twenty-four patients underwent bilateral pulmonary PC-RTR. Three cases (13%) had discordant histologies between the two sides. Two patients had teratoma on the right side and necrosis on the left side. One patient had vital carcinoma on the left side and necrosis on the right side.

Discussion

This study confirms an important finding, namely, that we cannot fully rely on the predictive value of the histologic findings in one anatomic site for PC-RTR in another anatomic site.

Approximately 20% of testicular cancer patients are overtreated and, due to the excellent survival rates, even in metastatic stages, treatment-related toxicities are the main cause for morbidity in these patients [15–17]. The reduction of treatment-related toxicity should be a central measure in decision making. Thus, the idea of avoiding unnecessary surgery is appealing, especially when the histologic result of one metastatic site is predictive of another.

In the present study, we evaluated both first-line and salvage patients. Since the therapeutic options after salvage chemotherapy are limited, the indication to resect residual masses in this setting is imperative. The associated willingness to take surgical risks surgery is particularly important in the salvage setting and must therefore be evaluated separately from the first-line setting.

Several groups have described discordant histologic findings when resection is performed at multiple sites. In the present study, we report a histologic discordance rate between retroperitoneal and thoracic histology of 23% after first-line treatment and 55% after salvage treatment. These findings are consistent with large series describing discordance between histologic findings from different sites ranging from 29 to 46% [11, 14, 18]. However, in contrast to these previous studies, we cannot confirm the predictive value of necrotic tissue in the retroperitoneum for an identical histology in thoracic residual masses. Steyerberg and Hartman both described that in the case of presence of necrotic tissue in the retroperitoneum, the probability of necrotic tissue in pulmonary lesions could be up to 90% [11, 14]. In our cohort, patients with necrosis only on retroperitoneal histology had a discordance with thoracic histology of 29% for first-line patients and 33% for salvage patients.

Complete concordance was found when comparing between histologic findings from retroperitoneal and extrapulmonary thoracic sites, all of which contained teratomous elements. This is most likely due to the common lymphogenic spread of retroperitoneal and thoracic lymphatic metastases.

Twenty-four patients underwent bilateral lung resection. In this cohort, the discordance of histologic findings on both sides was 13%. Already in 2009 Besse et al. described that in case of bilateral lung metastasis and necrosis on one side, the probability of the same histology on the other side is up to 95% [10]. In contrast, to these findings Schirren et al. described a discordance of histologic findings between left and right lung of 20% [9].

An important finding that could be used to predict treatment outcome and thus guide further decision making is the fact that all patients with teratomous findings at orchiectomy and retroperitoneal resection also had teratoma on thoracic histology. The current guideline recommendation also requires resection of the thoracic residues in the case of teratomas in the retroperitoneum [19].

Limitations

Although this study was conducted in one of the largest germ cell tumor referral centers in Germany, the cohort size presented is still small and did not allow for an analysis with statistically sound conclusions. In addition, the rarity of the disease limits efforts such as this

one to a retrospective analysis. Furthermore, patients with residual retroperitoneal and thoracic disease who did not undergo surgery were not evaluated in this study. In our center, indications for resection of residual tumors are generally residual masses larger than 1 cm. However, several factors may influence the decision to proceed with surgery. A high degree of tumor shrinkage after chemotherapy, a high proportion of seminoma or choriocarcinoma in the primary histology (which would typically contain only necrosis after chemotherapy), or poor patient health status may be factors that weigh in favor of surveillance. The data presented in this study are subject to a selection bias because all patients included in this study were selected for surgery at retroperitoneal and thoracic sites.

Conclusion

Based on our analysis, necrosis in the retroperitoneal specimen does not exclude vital carcinoma at another anatomical site. Therefore, we still recommend the resection of relevant residual thoracic metastases, even if the retroperitoneal specimen was only necrotic. If the retroperitoneal specimen contained teratoma, the thoracic residual masses are very likely to contain teratoma as well. Reliable prediction between retroperitoneal and extrapulmonary thoracic metastases is possible.

Abbreviations

PC-RTR	Postchemotherapy residual tumor resection
GCT	Germ cell tumor
EAU	European Association of Urology
NSGCT	Non seminomatous germ cell tumor
IGCCCG	International Germ Cell Cancer Cooperative Group
VIP	Cisplatin, ifosfamide and etoposide
BEP	Bleomycin, etoposide and cisplatin
EP	Etoposide and cisplatin
TI-CE	Paclitaxel and ifosfamide - carboplatin and etoposide
HCG	Human chorion gonadotropin
AFP	Alpha fetoprotein

Acknowledgements

None.

Author contributions

AH conceived the study. CW collected the data. All authors contributed to data. AH and PA were involved in planning and supervised the work. CW, YC, and AH processed the data, performed the analysis and designed the figures. YC and AH wrote the manuscript. All authors discussed the results and commented on the manuscript.

Funding

None.

Open Access funding enabled and organized by Projekt DEAL.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics statement

This retrospective study was approved by the local ethic committee (2019–720) of the University Hospital Düsseldorf of the Heinrich Heine University.

Competing interests

The authors declare no competing interests.

Conflict of interest

All authors disclose any conflict of interest.

Author details

¹Department of Urology, Medical Faculty, University of Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany

²Department of Thoracic Surgery, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany

³Division of Thoracic Surgery, Department of General and Visceral Surgery, Medical Faculty, University of Duesseldorf, Heinrich-Heine-University, Duesseldorf, Germany

Received: 24 May 2024 / Accepted: 10 July 2024

Published online: 17 July 2024

References

1. Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, Vickers AJ, Sheinfeld J. Improved clinical outcome in recent years for men with metastatic non-seminomatous germ cell tumors. *J Clin Oncol*. 2007;25(35):5603–8. <https://doi.org/10.1200/JCO.2007.13.6283>.
2. Vergouwe Y, Steyerberg EW, Foster RS, Sleijfer DT, Fossa SD, Gerl A, de Wit R, Roberts JT, Habbema JD. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. *Eur Urol*. 2007;51(2):424–32. <https://doi.org/10.1016/j.eururo.2006.06.047>.
3. Baessler B, Nestler T, Pinto Dos Santos D, Paffenholz P, Zeuch V, Pfister D, Maintz D, Heidenreich A. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection. *Eur Radiol*. 2020;30(4):2334–45. <https://doi.org/10.1007/s00330-019-06495-z>.
4. Miranda Ede P, Abe DK, Nesrallah AJ, dos Reis ST, Crippa A, Srougi M, Dall'Oglio MF. Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study. *World J Surg Oncol*. 2012;10:203. <https://doi.org/10.1186/1477-7819-10-203>.
5. Mosharafa AA, Foster RS, Koch MO, Bihle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. *J Urol*. 2004;171(5):1839–41. <https://doi.org/10.1097/01.ju.0000120141.89737.90>.
6. Baniel J, Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. *Semin Surg Oncol*. 1999;17(4):263–7. [https://doi.org/10.1002/\(sic\)1098-2388\(199912\)17:4%3C263::aid-ssu7%3E3.0.co;2-6](https://doi.org/10.1002/(sic)1098-2388(199912)17:4%3C263::aid-ssu7%3E3.0.co;2-6).
7. Kesler KA, Rieger KM, Hammoud ZT, Kruter LE, Perkins SM, Turrentine MW, Schneider BP, Einhorn LH, Brown JW. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. *Ann Thorac Surg*. 2008;85(2):371–8. <https://doi.org/10.1016/j.athoracsur.2007.09.020>.
8. Tognoni PG, Foster RS, McGraw P, Heilman D, Bihle R, Rowland RG, Wahle GR, Einhorn LH, Donohue JP. Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology. *J Urol*. 1998;159(6):1833–5.
9. Schirren J, Trainer S, Eberlein M, Lorch A, Beyer J, Bolukbas S. The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. *Thorac Cardiovasc Surg*. 2012;60(6):405–12. <https://doi.org/10.1055/s-0031-1299584>.
10. Besse B, Grunenwald D, Flechon A, Caty A, Chevreau C, Culine S, Theodore C, Fizazi K. Nonseminomatous germ cell tumors: assessing the need for post-chemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. *J Thorac Cardiovasc Surg*. 2009;137(2):448–52. <https://doi.org/10.1016/j.jtcvs.2008.09.032>.
11. Steyerberg EW, Donohue JP, Gerl A, Toner GC, Schraffordt Koops H, Fossa SD, Keizer HJ. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. *J Urol*. 1997;158(2):474–8. [https://doi.org/10.1016/s0022-5347\(01\)64506-3](https://doi.org/10.1016/s0022-5347(01)64506-3).
12. Kesler KA, Kruter LE, Perkins SM, Rieger KM, Sullivan KJ, Runyan ML, Brown JW, Einhorn LH. Survival after resection for metastatic testicular nonseminomatous germ cell cancer to the lung or mediastinum. *Ann Thorac Surg*. 2011;91(4):1085–93. <https://doi.org/10.1016/j.athoracsur.2010.12.034>. discussion 1093.
13. Kesler KA, Stram AR, Timsina LR, Turrentine MW, Brown JW, Einhorn LH. (2021) Outcomes following surgery for primary mediastinal nonseminomatous germ cell tumors in the cisplatin era. *The Journal of thoracic and cardiovascular surgery* 161 (6):1947–1959 e1941. <https://doi.org/10.1016/j.jtcvs.2020.01.118>.
14. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. *Eur J Cancer*. 1997;33(6):843–7. [https://doi.org/10.1016/s0959-8049\(96\)00517-5](https://doi.org/10.1016/s0959-8049(96)00517-5).
15. Paffenholz PPD, Heidenreich A. (2017) Nonguideline concordant treatment of testicular cancer. *Journal of Clinical Oncology* 35, no 6_suppl. https://doi.org/10.1200/JCO.2017.35.6_suppl.407.
16. Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, Dahl AA, Bremnes RM, Fossa SD. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. *J Clin Oncol*. 2012;30(30):3752–63. <https://doi.org/10.1200/JCO.2012.43.4431>.
17. Hellesnes R, Kvammen O, Myklebust TA, Bremnes RM, Karlsdottir A, Negaard HFS, Tandstad T, Wilsgaard T, Fossa SD, Haugnes HS. Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. *Int J Cancer*. 2020;147(1):21–32. <https://doi.org/10.1002/ijc.32704>.
18. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. *Semin Urol Oncol*. 2002;20(4):262–71. <https://doi.org/10.1053/suro.2002.36977>.
19. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J, European Association of U. Guidelines on testicular Cancer: 2015 update. *Eur Urol*. 2015;68(6):1054–68. <https://doi.org/10.1016/j.eururo.2015.07.044>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.